---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-128993"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:38:54.304373+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma CEO Usman Azam resigns; Lucinda Warren named Interim CEO

## Summary
- Usman Azam resigned as President, CEO and Board member effective March 26, 2026.
- Lucinda Warren, previously CFO and CBO, appointed Interim President and CEO effective March 27, 2026; retains CFO and CBO roles.
- Warren's base salary $525,000; eligible for 45% target bonus and up to 1.0% stock option upon financing milestone.
- Azam severance: lump sum $232,500 (3 months salary plus 25% of 2026 target bonus) plus up to 12 months COBRA.
- Warren receives $10,000/month supplemental until new CEO hired or 12-month anniversary, with lump sum if earlier.

## SEC filing metadata
- accession: 0001193125-26-128993
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000119312526128993/0001193125-26-128993-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000119312526128993/d120770d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-128993
- JSON: https://secwatch.observer/filing/0001193125-26-128993.json
- Plain text: https://secwatch.observer/filing/0001193125-26-128993.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.